Adicet Bio Inc (ACET)vsargenx NV ADR (ARGX)
ACET
Adicet Bio Inc
$3.81
0.00%
HEALTHCARE · Cap: $42.78M
ARGX
argenx NV ADR
$891.76
+1.05%
HEALTHCARE · Cap: $54.94B
Smart Verdict
WallStSmart Research — data-driven comparison
ARGX leads profitability with a 31.7% profit margin vs 0.0%. ACET appears more attractively valued with a PEG of 0.82. ARGX earns a higher WallStSmart Score of 73/100 (B).
ACET
Hold38
out of 100
Grade: F
ARGX
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ACET.
Margin of Safety
+67.5%
Fair Value
$2566.94
Current Price
$891.76
$1675.18 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Growing faster than its price suggests
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 36.3%
Revenue surging 52.1% year-over-year
Earnings expanding 50.6% YoY
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 165.8x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ACET
The strongest argument for ACET centers on Price/Book, Debt/Equity, PEG Ratio. PEG of 0.82 suggests the stock is reasonably priced for its growth.
Bull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 31.7% and operating margin at 36.3%. Revenue growth of 52.1% demonstrates continued momentum.
Bear Case : ACET
The primary concerns for ACET are EPS Growth, Market Cap, Profit Margin.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Key Dynamics to Monitor
ACET profiles as a value stock while ARGX is a growth play — different risk/reward profiles.
ACET carries more volatility with a beta of 1.63 — expect wider price swings.
ARGX is growing revenue faster at 52.1% — sustainability is the question.
ARGX generates stronger free cash flow (749M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (73/100 vs 38/100), backed by strong 31.7% margins and 52.1% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Adicet Bio Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company is headquartered in Boston, Massachusetts.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?